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Abstract: Cigarette smoking remains the largest preventable cause of premature death in 
developed countries. Until recently nicotine replacement therapy (NRT) has been the only 
recognised form of treatment for smoking cessation. Bupropion, the ﬁ  rst non-nicotine based 
drug for smoking cessation was licensed in the United States of America (US) in 1997 and in 
the United Kingdom (UK) in 2000 for smoking cessation in people aged 18 years and over. 
Bupropion exerts its effect primarily through the inhibition of dopamine reuptake into neuronal 
synaptic vesicles. It is also a weak noradrenalin reuptake inhibitor and has no effect on the 
serotonin system. Bupropion has proven efﬁ  cacy for smoking cessation in a number of clinical 
trials, helping approximately one in ﬁ  ve smokers to stop smoking. Up to a half of patients taking 
bupropion experience side effects, mainly insomnia and a dry mouth, which are closely linked 
to the nicotine withdrawal syndrome. Bupropion is rarely associated with seizures however care 
must be taken when co-prescribing with drugs that can lower seizure threshold. Also, bupropion 
is a potent enzyme inhibitor and can raise plasma levels of some drugs including antidepres-
sants, antiarrhythmics and antipsychotics. Bupropion has been shown to be a safe and cost 
effective smoking cessation agent. Despite this, NRT remains the dominant pharmacotherapy 
to aid smoking cessation.
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Introduction
Approximately one-quarter of adults in the United Kingdom (UK) smoke cigarettes 
with smoking being the largest single cause of death in the UK. Cigarette smoking is 
estimated to cost the National Health Service (NHS) approximately £1500 million per 
year (RCP 2000). Approximately half of all smokers will die prematurely as a result 
of smoking cigarettes and in the next 50 years about 450 million deaths worldwide 
will be attributable to smoking cigarettes (Jha et al 2006).
Until recently UK smokers have had little choice of agent or method when attempt-
ing to stop smoking. Prior to June 2000 the only pharmacotherapy available to help 
smokers quit was nicotine replacement therapy (NRT) prescribed on a private basis. 
In June 2000, bupropion (amfebutamone), an amphetamine-based drug, was licensed 
for use in smoking cessation in the UK and general practitioners were able to prescribe 
it within the NHS. The NHS prescription of NRT followed soon after in April 2001 
allowing free prescription to disadvantaged sections of society, who have a higher 
prevalence of smoking and associated morbidities (Jha et al 2006). These changes were 
in line with the UK government’s drive to address a major cause of morbidity and 
death in the UK with the publication of “Smoking Kills: A White Paper on Tobacco” 
(Secretary of State for Health 1998). Bupropion and NRT have continued to comple-
ment each other in the UK’s smoking cessation strategy (NICE 2002) with bupropion 
taking a 5% share of total prescribing for smoking cessation in the UK (Department of 
Health 2006). Additionally, varenicline, a selective nicotinic receptor partial agonist International Journal of COPD 2008:3(1) 46
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was licensed in the UK in December 2006 and recommended 
by NICE in July 2007 as an option for smokers who have 
expressed a desire to stop smoking (NICE 2007).
Bupropion was developed as an antidepressant for the 
treatment of major depressive disorder in 1989 as a thrice-daily 
immediate release formulation (Fava 2005). In 1996 a twice-
daily sustained release (SR) formulation was produced and, 
in 1997 the smoking cessation properties were ﬁ  rst noticed in 
the United States of America (US) (Tong et al 2006). Follow-
ing evaluation as an anti-smoking agent (Hurt et al 1997), it 
became licensed as an aid to smoking cessation and is now a 
recognised ﬁ  rst line antismoking agent in both the UK and US. 
However it has not been accepted into all health care systems 
throughout the world (Bloomﬁ  eld 2005). An extended release 
formulation became available in 2003 for the treatment of 
major depression, but it is the SR formulation that continues 
to be evaluated for its use in smoking cessation.
Bupropion is licensed for use in patients over the 
age of 18 years and is available in the SR formulation 
(GlaxoSmithKline 2006). Patients themselves set a target 
quit date, typically 2 weeks hence, and are prescribed 150 mg 
daily for 6 days followed by 150 mg twice daily for 7 to 
9 weeks. The ﬁ  rst prescription for bupropion should last 
approximately 4 weeks and take the patient beyond the target 
quit date. Those who return following successful cessation 
are given the remainder of the treatment course.
This review considers the cumulative evidence for the 
mechanism of action of bupropion, the recent evidence 
for its effectiveness as a smoking cessation agent, its cost 
effectiveness, its use in different clinical groups, and its 
safety proﬁ  le.
Method
A MEDLINE search was performed to select contemporary 
articles on bupropion for smoking cessation. The Medical 
Subject Heading (MeSH) terms ‘bupropion’ and ‘smoking 
cessation’ were applied and restricted to articles written in 
English. A total of 533 articles relating to the use of bupro-
pion for smoking cessation were included in the review. In 
addition, the reference lists of articles in the initial search 
were reviewed for other signiﬁ  cant papers to include in the 
review. No date limits were applied to the papers included 
from the bibliography search.
Metabolism and mechanism
of action
Bupropion is absorbed by the gut, metabolised extensively 
within the liver and excreted through the kidneys with a 
half-life of approximately 21 hours (Jefferson et al 2005). 
Bupropion is a potent inhibitor of cytochrome p450 2D6 
(Hesse et al 2003; Jefferson et al 2005; Kotlyar et al 2005; 
Wang et al 2006) and reduces the clearance of drugs metabo-
lised by this enzyme. The effects of bupropion are mediated 
via its metabolites: hydroxybupropion, threohydrobupropion 
and erythrobupropion (DTB 2000; Warner et al 2005).
Bupropion exerts its main mechanism of action through 
dopamine and noradrenalin reuptake inhibition with little 
serotonergic effect (Warner et al 2005). It also attenuates the 
stimulant effects of nicotine on the nicotinic acetylecholine 
receptors (Figure 1).
Cigarette smoking results in nicotine absorption into the 
blood stream and crosses the blood brain barrier. This in 
turn causes a release of dopamine into the synaptic cleft of 
the dopaminergic, pleasure-seeking pathways in the brain. 
Following a lowering of nicotine intake, dopamine reuptake 
into the axon terminal vesicles occurs. Bupropion is thought 
to exert its main effect by inhibiting this dopamine reuptake, 
probably by its inﬂ  uence on the dopamine transporter system 
(Warner et al 2005). However, bupropion appears to have dif-
fering effects on dopamine within different areas of the brain. 
In the nucleus accumbens, bupropion antagonises dopamine 
reuptake (Nomikos et al 1992) but has also been shown to 
increase striatal vesicular transport (Rau et al 2005) thus 
increasing reuptake from the synaptic cleft here. Dopamine 
reuptake inhibition in the nucleus accumbens reduces the 
dopamine deﬁ  ciency experienced in nicotine withdrawal and 
may explain the attenuating effect bupropion has on nicotine 
withdrawal symptoms.
Bupropion is also a weak noradrenalin reuptake inhibitor 
(Ascher et al 1995). This mechanism of action is credited 
with its antidepressant effects at higher doses than those 
used for smoking cessation (Fava et al 2005). Noradrenalin 
release from the hippocampus has been demonstrated in 
opiate withdrawal (Done et al 1992). A similar process may 
occur with other drugs of dependence including nicotine 
and bupropion has been shown to be of beneﬁ  t in treating 
patients who experience amphetamine addiction (Newton 
et al 2005), cocaine dependence (Poling et al 2006) and 
generalized addictive behaviors (Dannon et al 2005). The 
mechanism by which bupropion inﬂ  uences the noradrenergic 
system is poorly understood and continues to be a subject 
for investigation.
At the postsynaptic acetylcholine nicotinic receptor, 
bupropion antagonizes the effect of nicotine (Warner et al 
2005) and has been shown to block the pharmacological 
effects of nicotine in vivo (Slemmer et al 2000). Bupropion International Journal of COPD 2008:3(1) 47
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may also inhibit nicotine induced vesicular release of 
dopamine (Miller et al 2002). These effects may explain 
the ability of bupropion to break the reinforcing effect 
experienced by chronic nicotine addiction. What is unclear is 
whether bupropion exerts any longer term effects preventing 
relapse following cessation of treatment.
Smoking cessation
Bupropion is licensed for smoking cessation in both the UK 
and US and is recommended as a ﬁ  rst line agent for smok-
ing cessation (NICE 2002). Approximately 1 in 5 smokers 
successfully stop and remain non-smoking at one year with 
bupropion therapy (Table 1). The initial landmark trials of 
Hurt and Jorenby were conducted on healthy non-depressed 
patients and found comparable signiﬁ  cant one-year absti-
nence rates for bupropion therapy compared with placebo 
(23% vs 12%, p = 0.01, Hurt et al 1997; 30% vs 16%, p  
0.001, Jorenby et al 1999). A recent Cochrane systematic 
review of 19 randomized trials, showed that bupropion 
doubled the odds of smoking cessation over placebo (Odds 
ratio 2.06, 95% conﬁ  dence intervals 1.77 to 2.40; Hughes 
et al 2004). Highlights of the main double-blind randomized 
placebo-controlled trials are shown in Table 1.
Sixty percent of patients who attempt to stop smoking 
have had previous attempts to quit (Wilkes et al 2005). They 
often require repeated help from health professionals to 
eventually overcome their addiction (Errard-Lalande 2005) 
but the motivation that brings smokers back to try again will 
often lead to eventual success (Boardman et al 2005).
The efﬁ  cacy of bupropion appears not to diminish with 
repeated exposure (Rauhut et al 2005). Gonzales showed 
successful treatment with bupropion in a randomized placebo-
controlled trial of 450 patients who had previously failed 
with bupropion (Gonzales et al 2001). Six month continuous 
abstinence rates following treatment with bupropion SR 
150 mg bd versus placebo were 12% vs 2%, p  0.001. Some 
authors advocate supporting a smoking reduction policy 
(Hughes et al 2005), although six-month abstinence rates 
for smokers interested in reducing but not quitting smoking 
showed non-signiﬁ  cant results when compared with placebo 
Figure 1 The effect of bupropion in the synaptic cleft. Dopamine (DA), noradrenalin (NA) and serotonin (S).International Journal of COPD 2008:3(1) 48
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(7% vs 5%, p = 0.5: Hatsukami et al 2004). Only one study 
in Table 1 showed a non-signiﬁ  cant difference in one-year 
smoking cessation rates, but did show a signiﬁ  cant continuous 
abstinence rate at 7 weeks (50% vs 40%, p = 0.013; Zellweger 
et al 2005). These authors conclude that bupropion is a 
successful antismoking agent. Strategies to prevent relapse 
however following discontinuation of treatment need to be 
examined. Questions still remain over longer-term success 
with bupropion for smoking cessation following discontinua-
tion of treatment. Extended treatment of 14 weeks bupropion 
does not improve one year abstinence rates compared with 
placebo (33% vs 34% NS; Killen et al 2006).
The use of bupropion in disease speciﬁ  c 
patient groups
Bupropion has been trialed in healthy smokers, depressed 
smokers, smokers with cardiovascular disease (CVD) 
and smokers with chronic obstructive pulmonary dis-
ease (COPD). Bupropion, despite being developed as an 
antidepressant is no more effective in depressed patients 
compared with non-depressed patients and exerts its 
smoking cessation effects in ways other than alleviating 
depressive symptoms (Catley et al 2005). Co-prescribing 
with antidepressants however can lead to a reduced 
clearance of some antidepressants through the enzyme 
inhibitory effects of bupropion. This in turn can potenti-
ate the effect that antidepressants have in lowering seizure 
threshold for bupropion-induced seizures. In patients with 
established CVD, bupropion has similar success rates 
compared with healthy smokers (27% bupropion vs 11% 
placebo at 26 weeks, 22% vs 9% at 52 weeks, p  0.001; 
Tonstad et al 2003) and is recommended for this group of 
patients. The safety, tolerability and efﬁ  cacy of bupropion 
for smoking cessation in patients with COPD has also been 
established with one-year continuous abstinence rates of 
16% for bupropion compared with 9% for placebo (Tashkin 
et al 2001). One other trial on patients with COPD has 
shown modest success at 6 months with abstinence rates 
of 13% for bupropion and 10% for placebo (Wagena et al 
2005), however concern has been expressed recently that 
bupropion may elevate pulmonary pressure in these patients 
(Paganelli et al 2006). Not all patient groups have demon-
strated success with bupropion therapy, which appears to be 
relatively ineffective in smokers with schizophrenia (Evins 
et al 2005). Evins et al demonstrated a 16% abstinence rate 
at 4 weeks with bupropion compared with 0% for placebo 
but the effect did not persist beyond discontinuation of 
bupropion treatment.
Safety proﬁ  le
Adverse effects
A large post-marketing observational cohort study of 11,735 
patients found the most commonly reported adverse events 
reported were insomnia, nausea/vomiting and dizziness 
(Boshier et al 2003). There was no evidence of an increase in 
mortality at 12 weeks post treatment with bupropion. Seizures 
have been reported to occur at a rate of approximately 0.1% 
(GlaxoSmithKline 2006), although in a review of 221 clini-
cal efﬁ  cacy trials including over 4000 patients, no seizures 
were reported (Richmond and Zwar 2003).
Adverse effects of bupropion are experienced more often 
than with NRT though the discontinuation rate is similar 
between the two therapies. Approximately 9% of patients 
using either bupropion or NRT will discontinue treatment and 
a further 13% will stop treatment temporarily (Barrueco et al 
2005). Adverse effects are experienced by approximately 
half of those treated in the ﬁ  rst two weeks with only 6% 
reporting adverse effects by 3 months (Barrueco et al 2005). 
Pragmatic observational studies have shown between one 
third and two thirds of patients experience adverse effects 
with 30% stopping treatment due to adverse effects (Paluck 
et al 2006; Wilkes et al 2005). Table 1 shows the treatment 
discontinuation rates due to adverse events in the major 
explanatory trials of bupropion.
The main side effects experienced with bupropion 
are shown in Table 2. Nicotine withdrawal also causes 
symptoms that are similar to the side effects reported 
during bupropion therapy. This may partly explain why 
no signiﬁ  cant difference has been demonstrated between 
Table 2 Prevalence of side effects of bupropion SR (range %). 
Pooled data from trials in Table 1
 Placebo  %  Bupropion  %
Insomniaa 9–21  24–42
Headache 3–33  4–33
Dry mouthb 4–24  6–28
Rash/Pruritus 7  15
Rhinitis 12–17  10–14
Nausea/Vomiting 5–6  9–13
Dizziness 1–6 2–11
Anxiety 5–11  5–9
Flu syndrome  6–11  4–9
Taste perversion  5  6
Constipation 1  5–6
Sweating 3  5
Mood disorder  4  4
a Statistical signiﬁ  cance demonstrated in 4 trials (Hurt et al 1997; Jorenby et al 1999; 
Ahluwalia et al 2002; Dalsgard et al 2004).
b Statistical signiﬁ  cance demonstrated in 2 trials (Hurt et al 1997; Jorenby et al 1999).International Journal of COPD 2008:3(1) 50
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bupropion and placebo for most of the adverse effects in 
the trials. This theory was supported in the study by Hurt, 
where the prevalence of reported side effects was similar 
between both the low and high dose bupropion groups 
(Hurt et al 1997). A lower dose of bupropion may not be 
sufﬁ  cient to produce side effects nor to alleviate withdrawal 
symptoms. Varenicline has a similar side effect proﬁ  le to 
bupropion.
Other side effects of bupropion include tremor, 
gastrointestinal disturbance, impaired concentration, depres-
sion, chest pain, asthenia, tachycardia, hypertension, ﬂ  ushing, 
confusion, anorexia, tinnitus, visual disturbance, palpitations, 
hallucinations, abnormal dreams, parasthaesia, irritabil-
ity, incoordination, urinary retention, urinary frequency, 
Stevens Johnson syndrome, blood glucose disturbance, and 
exacerbation of psoriasis (GlaxoSmithKline 2006). A rarer 
reported side effect was subacute cutaneous lupus erythema-
tosis (Cassis et al 2005).
Contraindications
Bupropion is contraindicated in patients with a history of sei-
zure, bipolar affective disorder, eating disorders, pregnancy 
and breast feeding (GlaxoSmithKline 2006). Care must be 
taken when prescribing for elderly patients, those with liver 
or renal impairment and when co-prescribing with drugs that 
cause lowering of seizure threshold. Drugs that lower seizure 
threshold include antidepressants, antipsychotics, systemic 
corticosteroids, theophylline and tramadol. Patients who 
abuse alcohol or have sustained a head injury are also at risk 
of bupropion-induced seizure.
Drug interactions
Bupropion is a cytochrome p450 2D6 inhibitor (Kotlyar et al 
2005; Jefferson et al 2005) and has the effect of reducing the 
clearance of drugs metabolized by this enzyme (Wang et al 
2006). Drugs metabolized by cytochrome p450 2D6 include 
SSRIs, tricyclic antidepressants, beta blockers, propafenone, 
ﬂ  ecanide, risperidone and thioridazine (GlaxoSmithKline 
2006; DTB 2000). Co-prescribing bupropion with these drugs 
should be avoided.
The dangers of bupropion
Some authors have suggested that bupropion should not 
be used in pregnancy because of the higher frequency of 
cardiac malformations observed in a registry of pregnancies 
exposed to bupropion (Anon 2005). It has been shown to be 
cardiotoxic in overdose and should be considered as a cause 
in patients with unexplained widening of the QRS complex 
in the electrocardiograph (Curry et al 2005). Also there has 
been one reported case of myocardial infarction in an adoles-
cent taking bupropion, erythromycin, and methylphenidate 
(George et al 2005). Bupropion is more notably associated 
with risk of seizures. When prescribed to individuals without 
a past history of seizure or risk factor for their occurrence, 
this risk has recently been calculated at approximately 1 in 
6000 for ﬁ  rst time users of bupropion (Hubbard et al 2005). 
In overdose this risk doubles (Shepherd 2005). Other adverse 
effects of bupropion in overdose include dizziness, tremor, 
nausea and/or vomiting, drowsiness, tachycardia and hal-
lucination (Shepherd 2005).
Economics
Bupropion is a cost effective treatment for smoking cessa-
tion (Ross et al 2005). A systematic review of the clinical 
and cost effectiveness of bupropion concluded that bupro-
pion was superior to NRT, giving an incremental cost per 
quality adjusted life year gained (QALY) for bupropion of 
approximately one third less than that for NRT (Woolacott 
et al 2002). Using the Global Health Outcomes simulation 
model with 20 years follow up of 1.3 million men and women 
in the Swedish population, bupropion and NRT were com-
pared concluding that bupropion was more cost saving than 
NRT (Bolin et al 2006). The incremental cost per QALY for 
bupropion was approximately 725 Euro for men and 535 Euro 
for women (at 2001 prices).
NRT and bupropion are effective aids for smoking 
cessation and are considered ﬁ  rst line agents (Corelli et al 
2006). Bupropion however has met opposition when being 
introduced into some countries. There has been opposition to 
its introduction in New Zealand where PHARMAC, a body 
responsible for funding health service treatments, supports 
the prescribing of cheaper and effective alternatives such as 
clonidine and nortriptyline (Bloomﬁ  eld 2005). Nortriptyline 
and bupropion have been shown to be equally effective for 
smoking cessation (Hall et al 2005) but interestingly cloni-
dine and nortriptyline are not licensed for smoking cessation 
in many western countries (Corelli et al 2006).
Despite the clinical and cost effectiveness of bupropion 
being established, of the £100 million invested in smoking 
cessation services in the NHS in the past 12 months only 5% 
was spent on bupropion with 82% being consumed by NRT 
(Department of Health 2006).
Discussion
Bupropion is licensed as a ﬁ  rst line pharmacotherapy for 
smoking cessation in both the UK and US. Bupropion is International Journal of COPD 2008:3(1) 51
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effective in the early stages of smoking cessation withdrawal 
by attenuating the effects of nicotine withdrawal. This is most 
probably mediated by the inhibition of dopamine reuptake 
within the synaptic cleft. Craving may also be attenuated by 
the negative effect bupropion has on the nicotinic acetyl-
choline receptors in damping the stimulant effect of nicotine 
on the postsynaptic membrane. What is unclear is whether 
bupropion has any effect, either on the withdrawal or crav-
ing effects of cigarette smoking, following the withdrawal of 
bupropion treatment. Most of the large trials suggest that a 
positive beneﬁ  t with bupropion therapy may be sustained up 
to one year, but the early success demonstrated by Zellwegger 
et al (2005) was not sustained following withdrawal of 
treatment. This supports the theory that bupropion does not 
modify neurotransmitter activity and has no longer-term 
effects beyond the treatment period.
Anti-smoking treatments may be more successful if they 
are tailored to the individuals’ genetic susceptibility (Lerman 
et al 2006). Smokers carrying the dopamine DRD2-141C 
Ins/Del genotype were examined in an open-labelled ran-
domized trial and those carrying the Ins C allele were signiﬁ  -
cantly more likely to succeed with bupropion therapy while 
those with the Del C allele were more successful with NRT 
(Lerman et al 2006). To date, there has been no evidence to 
suggest that gender may inﬂ  uence the success or failure of 
bupropion therapy (Scharf and Shiffman 2004).
None of the clinical trials has shown signiﬁ  cant weight 
gain among patients undergoing bupropion therapy, an 
important factor to consider as many patients are concerned 
about weight gain when stopping smoking (Clark et al 
2005).
Primary health care physicians including general prac-
titioners and specially trained practice nurses are the best 
placed professionals to deliver smoking cessation services. 
Nurses within the NHS have been able to prescribe NRT 
for a number of year under the Extended Formulary for 
Nurse Prescribers scheme. From the 1st May 2006 Nurse 
Independent Prescribing legislation allows UK nurses to 
prescribe ‘any licensed medicine for any medical condition 
within their professional competencies’. Hence, bupropion 
and other pharmacological agents for smoking cessation can 
be prescribed by UK Smoking Cessation Specialist nurses 
(Department of Health 2007). The slow uptake of nurse 
prescribing, the British National Formulary recommenda-
tion of NRT as the ﬁ  rst line therapy for nicotine addiction 
and the belief that bupropion is not as safe as NRT (Vogt 
2006) may in part explain the low uptake of bupropion for 
smoking cessation. NHS patients who do not have access to 
these services within the primary care setting are referred to 
specialist smoking cessation clinics (West et al 2000; NICE 
2002). Dentists, who see the direct effects of smoking with 
nicotine staining of teeth and gingival disease, should also 
be involved with smoking cessation services (Covington et al 
2005). Bupropion therapy, delivered by dental practitioners, 
is equally effective when compared to general practitioners 
prescribing of bupropion (Nasry et al 2006) and this role 
of the dental practitioners has some support (Davis 2005; 
Pizzo et al 2006).
The smoker craves nicotine in an attempt to produce 
dopamine overﬂ  ow in the pleasure seeking areas of the brain. 
The reinforcing effects of nicotine thus drive the smoker in 
a quest for steady state neurotransmitter activity within the 
synaptic cleft. Bupropion therapy delivers this steady state, as 
does NRT, but at some time the smoker will cease treatment 
and neurotransmitter activity returns to the pre-smoking state. 
Whichever route the smoker takes in an attempt to give up 
smoking he/she will have to go through withdrawal at some 
stage, whether it is from nicotine in cigarettes, nicotine in 
NRT or bupropion therapy. Ultimately the smoker craves 
the steady state of neurotransmitter activity enjoyed by the 
non-smoker and it is the withdrawal symptoms experienced 
during the transition back to that steady state that smoking 
cessation therapies aim to alleviate.
Conclusion
Bupropion is an effective pharmacotherapy to aid smoking 
cessation (Ludvig et al 2005; Ross et al 2005) and should 
be considered as a ﬁ  rst line agent along with NRT alone 
or in combination (Mansourati et al 2005). Both pragmatic 
observational trials and explanatory randomized trials of 
bupropion therapy have shown approximately 1 in 5 smokers 
will successfully remain abstinent from smoking at one year 
(Hurt et al 1997; Jorenby et al 1999; Tonnesen et al 2003; 
Tonstad et al 2003; Zellweger et al 2005; Wilkes et al 2005; 
Paluck et al 2006). Varenicline is also considered as a ﬁ  rst 
line pharmacotherapy for motivated smokers expressing a 
desire to stop smoking (Frishman 2007; NICE 2007; Nides 
et al 2007). Varenicline’s initial higher quit rate compared to 
bupropion tails off to similar rates between the two drugs at 
one year (Gonzales et al 2006; Jorenby et al 2006; Oncken 
et al 2006; Tonstad et al 2006). Nortriptyline and clonidine 
have proven efﬁ  cacy for smoking cessation and are consid-
ered as second line agents for smoking cessation (McRobbie 
et al 2005). There is no evidence to support prolonged bupro-
pion therapy beyond its current license of 7 to 9 weeks and 
any decision to limit re-treatment is purely a pragmatic one International Journal of COPD 2008:3(1) 52
Wilkes
(Killen et al 2006). NICE recommend re-treatment after a 
period of six months (NICE 2002). Also there is only limited 
evidence that bupropion therapy has a modifying effect upon 
withdrawal and craving following cessation of treatment 
(Warner et al 2005).
The next steps in smoking cessation strategies for many 
countries are the introduction of smoking bans in public 
places. Bupropion, varenicline and NRT will however con-
tinue to play a signiﬁ  cant part in helping smokers to quit. 
Pharmacotherapies alone will not confer successful smoking 
cessation; psychological support and personal motivation as 
well as modifying environmental factors are paramount to 
successful smoking cessation.
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